WO2021065986A1 - 生細胞分離用容器 - Google Patents

生細胞分離用容器 Download PDF

Info

Publication number
WO2021065986A1
WO2021065986A1 PCT/JP2020/037090 JP2020037090W WO2021065986A1 WO 2021065986 A1 WO2021065986 A1 WO 2021065986A1 JP 2020037090 W JP2020037090 W JP 2020037090W WO 2021065986 A1 WO2021065986 A1 WO 2021065986A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
container
tissue
crushing
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/037090
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
りさ 結城
賢二 大山
勇 松田
文哉 大橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to JP2021551354A priority Critical patent/JP7546584B2/ja
Priority to CN202080062738.4A priority patent/CN114364784B/zh
Priority to EP20873204.0A priority patent/EP4026888A4/en
Publication of WO2021065986A1 publication Critical patent/WO2021065986A1/ja
Priority to US17/682,418 priority patent/US20220275316A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A61J1/12—Bag-type containers with means for holding samples of contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/14—Bags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/34—Internal compartments or partitions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M45/00—Means for pre-treatment of biological substances
    • C12M45/02—Means for pre-treatment of biological substances by mechanical forces; Stirring; Trituration; Comminuting
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/04—Cell isolation or sorting

Definitions

  • the present invention relates to a method for separating living cells from living body-derived tissues, a container for use in the same method, a kit for use in the same method, and a graft produced using the living cells obtained by the same method.
  • Patent Document 1 a three-dimensionally constructed cell culture containing skeletal myoblasts that can be transplanted into the heart and a method for producing the same have been provided (Patent Document 1).
  • the skeletal myoblasts used for such cell transplantation are usually obtained by separating CD56-positive cells such as skeletal myoblasts and muscle satellite cells from the skeletal muscle tissue to be transplanted, but the cells separated from the skeletal muscle tissue.
  • CD56-positive cells such as skeletal myoblasts and muscle satellite cells
  • a method of recovering cells contained in an enzyme-treated solution obtained by immersing the cells in a solution for a predetermined time and performing an enzyme treatment is known (Patent Document 2).
  • skeletal muscle tissue is composed of muscle fibers, and the parenchyma of the muscle fibers is a multinucleated cell surrounded by a plasma membrane, but CD56-positive such as muscle satellite cells and / or skeletal myoblasts, which are precursor cells thereof.
  • the present inventors have determined the number of viable cells recovered from progenitor cells and the like (hereinafter, also referred to as stem cells) by crushing biological tissues, particularly skeletal muscle tissues, by pressing.
  • the present invention has been completed by finding that the viability and purity can be improved.
  • the present invention relates to the following.
  • a container for crushing a sample by pressing The container having a container body having an opening and a partition separating the upper space and the lower space of the container body, and at least a part of the partition is not horizontal to the bottom of the container.
  • ⁇ 4> The container according to any one of ⁇ 1> to ⁇ 3>, wherein the partition is substantially F-shaped or substantially C-shaped.
  • ⁇ 5> The container according to ⁇ 4>, wherein the inclination of the substantially F-shape and / or the substantially C-shape is asymmetric.
  • ⁇ 6> The container according to any one of ⁇ 1> to ⁇ 5>, which further has a sealing portion.
  • ⁇ 7> The container according to any one of ⁇ 1> to ⁇ 6>, wherein the partition is formed by forming a seal.
  • ⁇ 8> The container according to any one of ⁇ 1> to ⁇ 7>, wherein the sample is a tissue derived from a living body.
  • ⁇ 9> The container according to any one of ⁇ 1> to ⁇ 8> for separating CD56-positive cells.
  • the separation time can be shortened, and the number of recovered viable cells, viability and purity of stem cells can be stabilized and increased.
  • FIG. 1 is a schematic diagram showing that muscle satellite cells (A) exist between the basement membrane (B) and the plasma membrane (C) of muscle fibers constituting skeletal muscle.
  • FIG. 2 shows a sample crushing container of the present invention, in which a protrusion is formed on the left side of the lower space 7 toward the opening by one partition.
  • FIG. 3 shows a sample crushing container of the present invention, in which a projecting portion projecting toward an opening is formed in the center of the lower space 7 by two V-shaped partitions.
  • FIG. 4 shows a tissue treatment liquid immediately after being crushed by pressing.
  • FIG. 5 shows a schematic view when the sample and the enzyme digestive juice are put into the sample crushing container and sealed.
  • FIG. 6 shows the changes in the sample before the crushing treatment (A) and after the crushing treatment for 2 minutes (B). It can be seen that most of the skeletal muscle tissue is suspended by crushing for 2 minutes.
  • FIG. 7 shows a comparison of the number of skeletal myoblasts separated by Comparative Example 6 (A) and Example 5 (B). It can be seen that (B) the number of cells is significantly increased by combining the crushing treatment for 2 minutes and the shredding treatment.
  • FIG. 8 shows the sheet-shaped cell culture obtained in Example 6.
  • the present invention includes a method for separating living cells from a living tissue, which comprises a step of crushing the collected tissue by pressing.
  • the cells isolated by the method of the present invention have a high number of viable cells recovered and viability, and contain a high proportion of stem cells.
  • the biological tissue is not particularly limited as long as it is derived from the living body, and for example, muscle tissue, adipose tissue, skin tissue, cartilage tissue, tendon tissue, ligament tissue, soft tissue, vascular tissue, brain tissue, and circulatory organ. It is a systematic tissue, a digestive system tissue, a metabolic system tissue, a lymphatic system tissue, a bone marrow tissue, blood, etc., preferably muscle tissue, adipose tissue, bone marrow tissue, blood, and more preferably skeletal muscle tissue.
  • the living cells in the present disclosure can include any living cells isolated from living tissue.
  • myocardial cells fibroblasts, epithelial cells, endothelial cells, hepatocytes, pancreatic cells, renal cells, adrenal cells, root membrane cells, gingival cells, osteomyelocytes, skin cells, synovial cells, cartilage cells, etc.
  • stem cells eg, myoblasts (eg, skeletal myoblasts), muscle satellite cells, mesenchymal stem cells (eg, bone marrow, adipose tissue, peripheral blood, skin, hair roots, muscle tissue, endometrial, placenta, umbilical cord) Blood-derived cells, etc.), tissue stem cells such as heart stem cells, embryonic stem cells, etc.).
  • the living cell in the present invention may be a cell localized in direct contact with or adjacent to a plurality of membranes so as to be surrounded by the membranes among a plurality of membranes in contact with each other in a plane.
  • the living cells preferably include CD56-positive cells in skeletal muscle tissues such as skeletal myoblasts and muscle satellite cells, or mesenchymal stem cells derived from bone marrow, adipose tissue, and peripheral blood.
  • the biological tissue used in the present invention can be derived from any organism. Such organisms include, but are not limited to, for example, humans, non-human primates, rodents (mouse, rat, hamster, guinea pig, etc.), dogs, cats, pigs, horses, cows, goats, sheep and the like. ..
  • the biological tissue used in the present invention is obtained by using autologous cells isolated from the biological tissue collected from the transplant target (recipient) itself. , Rejection can be avoided.
  • the pressing in the present invention is derived from a living body by loosening the bonds inside the living body tissue such as between tissues, between tissues and cells and / or between cells by pressing from the outside of the living body-derived tissue, and by continuously crushing the bonds.
  • the living cells that make up the tissue, especially the cells that are localized inside the tissue, can be separated without damage. Therefore, if the pressing of the biological tissue collected in the present invention can loosen the internal bond of the tissue, even if it is applied directly to the biological tissue, it is applied from the outside of the container in which the biological tissue is charged through the container. You may.
  • the tissue When the biological tissue is directly pressed, for example, the tissue is fixed with tweezers or the like in a state where the biological tissue is put into a petri dish containing a physiologically acceptable liquid, and the tissue is pressed a plurality of times.
  • pressing through a container it can be carried out by charging the container (for example, a bag-shaped container) together with a physiologically acceptable liquid, fixing the container, and pressing the container itself a plurality of times.
  • the pressing in the present invention is preferably performed through a container containing a biological tissue. Not only can the biological tissue inside the container be directly pressurized by pressing through the container, but also the biological tissue inside the container can be pressurized by the water flow generated by the physiologically acceptable movement of the liquid. Can be crushed uniformly and efficiently.
  • grinding treatment or ultrasonic treatment is used, and these treatments directly destroy and homogenize the structure inside the tissue. This separates the cells, which is different from the pressing crushing of the present invention.
  • any method can be used for pressing as long as a shearing force that does not destroy living cells is generated while loosening the bonds inside the tissue, and the method may be manual or mechanical. Machines are preferred for crushing without raising the temperature.
  • a paddle-type homogenizer is typically preferred when pressing through a container.
  • the same portion of the container may be continuously pressed, but the biological tissue inside the container is uniformly pressurized and water flow is generated in the container. It is preferable to press at least two or more places of the container sequentially, for example, alternately at two places because it can be promoted.
  • a step of cutting the collected biological tissue before the step of crushing by pressing for example, a step of cutting into about 1 to 10 mm square, preferably about 5 mm square can be optionally provided.
  • the paddle type homogenizer presses the container containing the sample between the paddle that reciprocates toward the container containing the sample and the pressing portion provided opposite to the paddle to press the sample in the container.
  • a crushing device can be used.
  • a sample accommodating portion in which a container containing a sample can be arranged is provided between the opening / closing door and the paddle surface, and two paddles and an opening / closing door (pressing portion) provided on the paddle surface in the sample accommodating portion are provided.
  • a homogenizer can be used that alternately presses the container between and. Examples of such a device include homogenizers such as Promedia SH-IIM (Elmex, code No.
  • SH-2M bag homogenizer BH-W (As One), and BagMixerR (InterScience, product code .021-110). Be done.
  • a flat plate-shaped paddle or an uneven paddle can be used, and in order to sufficiently crush the biological tissue, the flat plate-shaped paddle and the uneven paddle are alternately pressed. Is preferable.
  • An example is the homogenizer described in JP-A-07-284679.
  • the crushing in the present invention requires that a part of the biological tissue is crushed to the extent that it is dispersed or suspended in a physiologically acceptable liquid, and is crushed to the extent that it is uniformly dispersed or suspended. I don't need it.
  • Such crushing may be, for example, crushing the average tissue length of the living body-derived tissue to about 4 mm square or less, about 3 mm square or less, about 2 mm square or less, and about 1 mm or less.
  • Such pulverization is, for example, a treatment of 30 seconds to 30 minutes, 2 to 15 minutes, 3 to 15 minutes with a paddle type homogenizer, and 1 to 5 minutes from the viewpoint of obtaining a certain amount of recovered viable cells while preventing a decrease in viability. Treatment is preferable.
  • the physiologically acceptable liquid is not particularly limited as long as the cells contained in the living tissue can survive, and for example, a proteolytic enzyme solution, water, physiological saline, and various buffer solutions (for example, PBS). , HBSS, etc.), various liquid media (eg, DMEM, MEM, F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 131, 153, 199, etc.), L15, SkBM, RITC80-7, DMEM / F12, etc. ) Etc. can be mentioned.
  • the physiologically acceptable liquid may contain antimicrobial agents such as antibiotics and antifungal agents.
  • the proteolytic enzyme solution contains proteolytic enzymes such as collagenase and matrix metalloproteinase that decompose fibrous tissue, trypsin that separates cell-cell adhesion and cell-culture substrate adhesion, and TrypLE Select (Life Technologies). But it may be.
  • the proteolytic enzyme solution may contain one or more proteolytic enzymes, for example, both collagenase and trypsin.
  • the concentration of collagenase may be 0.01 to 0.25% (W / V), and the concentration of trypsin may be 0.001 to 0.25% (V / V).
  • trypsin-EDTA (1 ⁇ ) solution can be used as trypsin
  • collagenase A (Roche Applied Science)
  • Collagenase Lyophilized (Clostridium Histolyticum origin, Life Technologies) can be used as collagenase.
  • Liberase MNP-S (Roche Applied Science) can be used.
  • an excess amount of proteolytic enzyme with respect to the amount of protein contained in the biological tissue. For example, when the weight of skeletal muscle tissue is 1 to 2 g, an excess amount of proteolytic enzyme is added when 20 mL of TrypLE Select containing 0.5 mg / L of collagenase A is added.
  • the proteolytic enzyme solution may contain EDTA or EGTA, which are calcium ion chelators.
  • the concentration of EDTA or EGTA may be 0.02 to 0.1% (W / V). If EDTA or EGTA is not included in the proteolytic enzyme, prepare a solution of EDTA or EGTA separately from the proteolytic enzyme, and prepare the solution of EDTA or EGTA before putting the biological tissue into the proteolytic enzyme solution. For example, it is preferable to immerse in.
  • the concentration of EDTA or EGTA in this case may also be 0.02 to 0.1% (W / V).
  • the volume of the physiologically acceptable liquid to be charged into the container is not particularly limited as long as the biological tissue can be uniformly pressed and crushed.
  • a commercially available homogenized bag for example, PYXON-20 series (Elmex, code No. PX0020, etc.), for example, 300 mL or less, 200 mL or less, 100 mL or less, 75 mL or less, 50 mL or less, 25 mL or less, 20 mL or less, 10 mL or less or It can be 7.5 mL or less, and 15 mL is preferable from the viewpoint that the skeletal muscle tissue can be uniformly pulverized and dispersed.
  • the cut skeletal muscle tissue and the physiologically acceptable liquid may be charged separately, or a mixture of these in a separate container in advance may be charged.
  • the temperature of the liquid is not particularly limited as long as it does not reduce the viability of skeletal myoblasts and the number of viable cells collected, but can be, for example, 4 to 37 ° C, 10 to 30 ° C or 15 to 25 ° C, which is typical. It is at room temperature.
  • the container used for the crushing step when pressed through a container, has flexibility enough to crush the sample by pressing from the outside of the container.
  • the container may be any container having airtightness and strength such that the sample containing the skeletal muscle tissue and the liquid does not leak while the container is pressed.
  • the shape of the container is not limited to a bottle shape, a tubular shape, a tube shape, a box shape, etc., but the container can be crushed evenly by pressing, and strength that can withstand continuous pressing is imparted.
  • a bag-shaped container is preferable because it can be used.
  • a bag-shaped container In the case of a bag-shaped container, it may have a polygonal shape (square shape) or a shape having a curved contour with reduced corners. Specific examples thereof include a bottom seal bag, a side seal bag, a three-way seal bag, a pillow bag, a gusset bag, a standing pouch, and a circular seal bag.
  • the material of the sample crushing container when pressing through a container, may be airtight and strong enough to withstand continuous pressing, and a resin film or sheet may be used.
  • a resin film or sheet may be used.
  • the material of the film or sheet for example, one or more selected from polystyrene, polyethylene, polypropylene, nylon, polyester, polycarbonate, synthetic rubber and the like can be used.
  • the resin film or sheet may have a single-layer structure or a laminated structure in which the same or different materials are laminated.
  • the thickness of the container is not particularly limited, but usually, for example, a container having a thickness within the range of 100 ⁇ m or less is used.
  • the size of the sample crushing container can be appropriately selected by those skilled in the art depending on the pressing method and the equipment used, and is not particularly limited.
  • a commercially available homogenized bag can be used in addition to a square bag-shaped container in which both side edges and bottom edges of the polyethylene sheet are heat-sealed.
  • Commercially available homogenized bags include, for example, PYXON-20 series (Elmex, code No.PX0020, etc.), Sanispec test bag (AS ONE, Catalog No.2-6391-02), RollBagR (InterScience, Ref.145 040) BagFilter.
  • a bag filter InterScience, Ref.111 720 or the like can be used.
  • Commercially available homogenized bags may or may not have a filter inside the bag, but homogenized bags with a filter are more expensive because they can cause friction between the skeletal muscle tissue and the filter inside the bag. It is thought that it exerts shearing force.
  • the pressing may be applied to the container containing the sample via the cushioning material. That is, the container containing the sample may be pressurized through the pressing applied to the cushioning material. Pressurizing the container containing the sample through pressing against the cushioning material can increase the number of viable stem cells collected and the viability. It is presumed that the impact at the time of pressing can be softened by the cushioning material and pressurized, which makes it possible to loosen the bond of the tissue without destroying the cells.
  • the cushioning material is not particularly limited as long as it is a material that can absorb the impact at the time of pressing, and for example, an elastic body such as rubber, cloth or styrofoam, or a bag-shaped container containing a liquid, gel or powder may be used. it can.
  • the cushioning material is preferably a bag-shaped container containing a liquid from the viewpoint that the pressure due to pressing can be transmitted in close contact with the container containing the sample.
  • the size of the cushioning material when pressing through a container, can be appropriately selected as long as it can soften the impact at the time of pressing and can adhere to the container containing the sample, for example, a paddle type homogenizer.
  • the bag-shaped container containing the liquid has the same size as the container for pressing the sample.
  • the volume of the liquid to be contained is not particularly limited as long as it can be pressurized by softening the impact at the time of pressing.
  • Those skilled in the art can appropriately select according to the pressing method and the equipment used, and when pressing using a commercially available homogenized bag, for example, PYXON-20 series (Elmex, code No. PX0020, etc.), about 20 mL to 300 mL , 50 mL to 200 mL, 75 mL to 100 mL, preferably 100 mL.
  • the biological tissue that has undergone the crushing step contains a higher number of recovered viable cells, viability, and a higher proportion of stem cells than those isolated without the step.
  • the number of viable cells recovered and the viability were 1.0 ⁇ 10 3 or more, 1.0 ⁇ 10 4 or more, 1.0 ⁇ 10 5 or more, and 1.0 ⁇ , respectively, after undergoing the enzyme treatment step described later.
  • 10 6 or more, and 80% or more, 85% or more may be 90% or more or 95% or higher.
  • the proportion of stem cells is 60% or higher, 65% or higher, 70% or higher, 75% or higher, 80% or higher, 85% after 3 passages of the cell population that has undergone the enzyme treatment step described below. As mentioned above, it can be 90% or more or 95% or more.
  • the number of viable cells recovered and viability can be determined using any known technique.
  • a method for example, the total number of recovered cells and the number of viable cells are counted by using a cell double staining method or the like, and the total number of viable cells is divided by the total number of cells.
  • the proportion of skeletal myoblasts can be determined using any known technique.
  • Such a technique includes, for example, labeling with an antibody specific for skeletal myoblasts and / or myosatellite cells, and dividing the number of positive cells to which the antibody is bound by the total number of cells counted.
  • Cell counting can be performed by microscopic observation of a specimen stained with a specific antibody, image analysis of a microscopic image, flow cytometric analysis of a cell population stained with a specific antibody, or the like.
  • the marker specific to the cell is not limited, for example, CD56, ⁇ 7 integrin, myosin heavy chain IIa, myosin heavy chain IIb, myosin heavy chain IId (IIx). , MyoD, Myf5, myogenin and the like.
  • Markers in which stem cells are specific to muscle satellite cells include, but are not limited to, CD56, CD34, Myogenin, Myf5, Pax7 and the like.
  • the separation method of the present invention may or may not include a step of crushing followed by a step of shredding. If the crushing step does not include a shredding step, the crushing step may be followed by an enzyme treatment step described below.
  • shredding refers to making a target tissue into smaller pieces of tissue by using a physical means such as an instrument.
  • the step of crushing is followed by the step of slicing, the pressed tissue crushing solution is transferred to a container for slicing such as a petri dish, and the crushed skeletal muscle tissue is further shredded.
  • the connective tissue (white tissue) in the crushed solution may be removed before starting shredding.
  • the separation method may be combined with a known physical cell separation method such as a step of grinding or a step of ultrasonically crushing instead of the step of crushing after the step of crushing.
  • a known physical cell separation method such as a step of grinding or a step of ultrasonically crushing instead of the step of crushing after the step of crushing.
  • An enzyme treatment step may be performed after the shredding step.
  • the biological tissue treated product is subjected to the enzyme treatment, and the cells are recovered from the enzyme treatment solution.
  • the enzyme treatment can be performed by immersing the biological tissue treated product in a proteolytic enzyme solution for a predetermined time.
  • the proteolytic enzyme solution has already been described above.
  • the treatment temperature of the enzyme treatment depends on the optimum temperature of the enzyme used, the deactivation temperature, etc., but is generally preferably 35 to 40 ° C.
  • the volume of the enzyme solution is preferably the volume at which the entire treated product is immersed in order to destroy the connective tissue of the entire biological tissue treated product. Further, it is preferable to stir during the enzyme treatment.
  • the method for recovering cells from the enzyme-treated solution is not particularly limited, and for example, a method for recovering a precipitate obtained by allowing the enzyme-treated solution to stand or centrifuge, or obtaining the enzyme-treated solution by allowing it to stand or centrifuge.
  • a method for recovering a precipitate obtained by allowing the enzyme-treated solution to stand or centrifuge or obtaining the enzyme-treated solution by allowing it to stand or centrifuge.
  • examples thereof include a method of collecting the supernatant and the precipitate separately, collecting the precipitate as it is, further filtering the supernatant, and centrifuging the filtered supernatant to recover the obtained precipitate.
  • undigested muscle tissue may be separated using a cell strainer or the like and used for further enzyme treatment.
  • the cells recovered by the separation method of the present invention may be further subjected to a culture step and a subculture step in which the cultured cells are subcultured.
  • Cell culture and passage can be performed using any known method.
  • the cells recovered by the separation method of the present invention may be further subjected to a gene transfer step for introducing a gene.
  • the gene to be introduced is not particularly limited as long as it is useful for the treatment of the disease to be treated, and may be, for example, a cytokine such as HGF.
  • any known method such as calcium phosphate method, lipofection method, ultrasonic introduction method, electroporation method, particle gun method, adenovirus vector, retrovirus vector or other viral vector utilization method, microinjection method, etc. can be used. Can be done using.
  • sample crushing container that can be used when pressing through the container.
  • the present invention is a container for crushing a sample by pressing, and has a container body having an opening and a partition separating the upper space and the lower space of the container body, and at least a part of the partition is provided.
  • the sample in the container moves to the other paddle side which is not operating, and when the other paddle is pressed, the sample moves to the one paddle side which is not operating.
  • the container body has a partition that separates the upper space and the lower space, the movement of the sample can be restricted to the lower space at the time of pressing, whereby the biological tissue can be efficiently and directly pressurized. ..
  • at least a part of the partition has a portion that is not horizontal with respect to the bottom of the container, for example, an inclination, so that the sample that has moved in the upper direction moves along the inclination, so that the movement of the sample in the lower space is in a specific direction. Since it can act as a guide to guide the water flow, it is possible to promote the generation of water flow at the time of pressing. Since such a water stream can pressurize and agitate the biological tissue, the biological tissue can be crushed more uniformly and efficiently.
  • Such a partition is not limited as long as it has a portion that is not horizontal to the bottom of the container, and may be, for example, a straight line or a curved line.
  • a tapered structure such as a substantially triangular pyramid shape or a substantially dome shape can be mentioned.
  • Such dividers may consist of any number, eg, one or more (two, three, four, five or six) dividers.
  • the volume ratio of the upper space to the lower space formed by the partition is not particularly limited as long as the movement of the living body-derived tissue is restricted as compared with before the partition is provided.
  • the upper space and the lower space are defined as 1 to 100: It may be separated by a volume ratio of 1, 1 to 50: 1, 1 to 25: 1, 1 to 10: 1.
  • the partition may be provided by any means as long as the upper space and the lower space can be separated.
  • the container body may be fractionated by heat welding (heat sealing), crimping, adhesive, etc., or the same as the container.
  • a partition member made of any different material may be provided on the container body by heat welding (heat sealing), pressure bonding, adhesion, or the like.
  • a part of the upper space is gripped when the opening / closing door of the pressing homogenizer is closed, so that the sample crushing container can be fixed.
  • the container has a communication hole that allows communication between the upper space and the lower space. Samples can be loaded and / or removed into the lower space through such communication holes.
  • the communication hole may be provided anywhere as long as the sample can be put into the lower space through the upper space, but by providing the communication hole at the top of the protruding portion of the lower space, it becomes easy to take out the sample. In particular, if the tip of the pipette is inserted into the communication hole and the sample is sucked out at the time of taking out, the sample in the lower space can be taken out without leaving behind.
  • the communication hole does not necessarily have to realize both loading and unloading of the sample, and even if the communication hole 5 for the purpose of loading the sample is located at any place other than the protruding portion, the protruding portion is formed after the crushing treatment.
  • the tip of the pipette may be inserted and removed from the top of the pipette by cutting the top of the pipette.
  • the communication hole when the communication hole is provided, it has a sealing portion that prevents the sample from moving to the upper space.
  • the sealing portion may be any sealing means as long as it can be accommodated in the lower space so that the sample does not move to the upper space through the communication hole when pressed, and a sealing member such as a zipper or a chuck made of any material same or different from the container. May be provided to the container body by heat welding (heat sealing), crimping, bonding, etc., and for example, the container body may be sealed by heat welding (heat sealing), crimping, adhesive, or the like.
  • the container 10 includes a container body 1 having an opening 4 and a partition 3 that separates the container body 1 into an upper space and a lower space. It has one partition (FIG. 2) and two partitions (FIG. 3) that are not horizontal to the bottom of the container.
  • FIGS. 2 and 3 the container 10 includes a container body 1 having an opening 4 and a partition 3 that separates the container body 1 into an upper space and a lower space. It has one partition (FIG. 2) and two partitions (FIG. 3) that are not horizontal to the bottom of the container.
  • the partition 3 may not completely separate the upper space 6 and the lower space 7, and may have a communication hole 5 that allows the upper space 6 and the lower space 7 to communicate with each other.
  • a sample containing a biological tissue and a physiologically acceptable liquid can be added to and / or removed from the lower space 7 through the communication hole 5.
  • the communication hole 5 is sealed with a heat seal or the like.
  • FIG. 2 is a container preferably used when pressing the same portion of the lower space 7, and a partition 3 is provided so that a protrusion is formed on the upper left of the lower space 7.
  • FIG. 3 is a container preferably used when pressing the left side and the right side of the lower space 7 alternately at regular intervals, and a V-shaped protrusion is formed in the center of the lower space 7 through a communication hole 5. Two partitions 3 are arranged so as to be.
  • the "graft” means a structure for transplantation into a living body, and particularly means a structure for transplantation containing cells as a constituent component.
  • the implant is a structure for transplantation that is free of cells and structures other than cell-derived substances (eg, scaffolds, etc.).
  • the implants in the present disclosure include, but are not limited to, sheet-like cell cultures, spheroids, cell aggregates, and the like, preferably sheet-like cell cultures or spheroids, and more preferably sheet-like cells. It is a culture.
  • sheet-shaped cell culture refers to cells connected to each other to form a sheet.
  • the cells may be linked to each other directly (including those via cell elements such as adhesion molecules) and / or via intervening substances.
  • the intervening substance is not particularly limited as long as it is a substance capable of at least physically (mechanically) connecting cells to each other, and examples thereof include an extracellular matrix.
  • the mediator is preferably derived from cells, particularly from the cells that make up the sheet-like cell culture.
  • the cells are at least physically (mechanically) connected, but may be more functionally, for example, chemically or electrically connected.
  • the sheet-like cell culture may be composed of one cell layer (single layer) or two or more cell layers (laminate (multilayer), for example, two layers, three layers, etc. It may be 4 layers, 5 layers, 6 layers, etc.). Further, the sheet-shaped cell culture may have a three-dimensional structure having a thickness exceeding the thickness of one cell without showing a clear layered structure of the cells. For example, in the vertical cross section of a sheet-shaped cell culture, cells may be present in a non-uniformly (for example, mosaic-like) arrangement without being uniformly aligned in the horizontal direction.
  • a non-uniformly for example, mosaic-like
  • the grafts of the present disclosure preferably do not contain scaffolds (supports). Scaffolds may be used in the art to attach cells to and / or inside the scaffold to maintain the physical integrity of the implant, such as a sheet cell culture, eg, poly. Although membranes made of vinylidene fluoride (PVDF) and the like are known, the implants of the present disclosure can maintain their physical integrity without such scaffolds. In addition, the implants of the present disclosure preferably consist only of cell-derived substances constituting the implants and do not contain any other substances.
  • scaffolds supports
  • Scaffolds may be used in the art to attach cells to and / or inside the scaffold to maintain the physical integrity of the implant, such as a sheet cell culture, eg, poly.
  • PVDF vinylidene fluoride
  • the implants of the present disclosure can maintain their physical integrity without such scaffolds.
  • the implants of the present disclosure preferably consist only of cell-derived substances constituting the implants and do not contain any other substances.
  • the cell may be a heterologous cell or an allogeneic cell.
  • heterologous cell means a cell derived from an organism of a species different from the recipient when the graft is used for transplantation.
  • cells derived from monkeys and pigs correspond to heterologous cells.
  • homoogeneous cell means a cell derived from an organism of the same species as the recipient.
  • the human cell corresponds to an allogeneic cell. Allogeneic cells include autologous cells (also referred to as autologous cells or autologous cells), ie, recipient-derived cells and allogeneic non-autologous cells (also referred to as allogeneic cells).
  • Autologous cells are preferred in the present disclosure because they do not cause rejection when transplanted. However, it is also possible to utilize heterologous cells and allogeneic non-autologous cells. When using heterologous cells or allogeneic non-autologous cells, immunosuppressive treatment may be required to suppress rejection.
  • cells other than autologous cells that is, allogeneic non-self-derived cells and allogeneic non-self-derived cells may be collectively referred to as non-autologous cells.
  • the cells are autologous cells or allogeneic cells.
  • the culture substrate is not particularly limited as long as the cells can form a cell culture on the cells, and includes, for example, containers of various materials and / or shapes, solid or semi-solid surfaces in the containers, and the like. ..
  • the container preferably has a structure / material that does not allow a liquid such as a culture solution to permeate.
  • Such materials include, without limitation, for example, polyethylene, polypropylene, Teflon®, polyethylene terephthalate, polymethylmethacrylate, nylon 6,6, polyvinyl alcohol, cellulose, silicon, polystyrene, glass, polyacrylamide, polydimethyl.
  • Acrylamide, metals (eg, iron, stainless steel, aluminum, copper, brass) and the like can be mentioned.
  • the container preferably has at least one flat surface.
  • a culture container having a bottom surface made of a culture substrate capable of forming a cell culture and a liquid-impermeable side surface.
  • a culture vessel include, but are not limited to, a cell culture dish, a cell culture bottle, and the like.
  • the bottom surface of the container may be transparent or opaque. If the bottom surface of the container is transparent, cells can be observed and counted from the back side of the container.
  • the container may have a solid or semi-solid surface inside the container. Examples of the solid surface include plates and containers of various materials as described above, and examples of the semi-solid surface include gels and soft polymer matrices.
  • the culture substrate may be prepared using the above-mentioned materials, or a commercially available one may be used.
  • Preferred culture substrates include, without limitation, for example, a substrate having an adhesive surface suitable for forming a sheet-like cell culture, and a substrate having a low adhesive surface suitable for forming spheroids. And / or a substrate having a uniform well-like structure and the like.
  • a substrate coated with a hydrophilic compound such as corona discharge-treated polystyrene, collagen gel or hydrophilic polymer on the surface thereof, and further, collagen.
  • Fibronectin Fibronectin, laminin, vitronectin, proteoglycan, glycosaminoglycan and other extracellular matrix, and base materials coated with cell adhesion factors such as cadoherin family, selectin family and integrin family on the surface.
  • base material is commercially available (for example, Corning (R) TC-Treated Culture Dish, Corning, etc.).
  • spheroid formation for example, soft agar, temperature-responsive gel obtained by cross-linking poly (N-isopropylacrylamide) (PIPAAm) with polyethylene glycol (PEG), polyhydroxyethyl methacrylate (commercially available name: mebiol gel), polyhydroxyethyl methacrylate ( Examples include a base material coated with a non-cell adhesive compound such as a hydrogel such as poly-HEMA) and 2-methacryloyloxyethyl phosphorischoline (MPC) polymer and / or a base material having a uniform uneven structure on the surface. Be done. Such substrates are also commercially available (eg, EZSPHERE (R), etc.).
  • the culture medium may be transparent or opaque in whole or in part.
  • the surface of the culture substrate may be coated with a material whose physical properties change in response to irritation, for example, temperature or light.
  • a material whose physical properties change in response to irritation, for example, temperature or light.
  • Such materials include, but are not limited to, for example, (meth) acrylamide compounds, N-alkyl substituted (meth) acrylamide derivatives (eg, N-ethylacrylamide, Nn-propylacrylamide, Nn-propylmethacrylamide, etc.
  • Known materials such as a copolymer with a body and a photoresponsive material such as N-isopropylacrylamide gel containing spirobenzopyran can be used (see, for example, JP-A-2-21186 and JP-A-2003-33177). ). By giving a predetermined stimulus to these materials, their physical characteristics, for example, hydrophilicity and hydrophobicity can be changed, and the exfoliation of the cell culture adhering on the material can be promoted. Culture dishes coated with a temperature-responsive material are commercially available (eg, CellSeed Inc.'s UpCell (R)) and can be used in the production methods of the present disclosure.
  • a temperature-responsive material are commercially available (eg, CellSeed Inc.'s UpCell (R)) and can be used in the production methods of the present disclosure.
  • the culture medium may have various shapes.
  • the area thereof is not particularly limited, but may be, for example, about 1 cm 2 to about 200 cm 2 , about 2 cm 2 to about 100 cm 2 , about 3 cm 2 to about 50 cm 2 .
  • a circular culture dish having a diameter of 10 cm can be mentioned. In this case, the area is 56.7 cm 2 .
  • the culture surface may be flat or may have an uneven structure. When it has a concavo-convex structure, it is preferable that it has a uniform concavo-convex structure.
  • the culture substrate may be coated with blood-derived components and / or cell adhesion components in order to form higher density implants, especially sheet-like cell cultures.
  • "Coated with blood-derived components and / or cell-adhesive components” means a state in which blood-derived components such as serum and / or cell-adhesive components are attached to the surface of the culture medium. The state can be obtained without limitation, for example, by treating the culture medium with blood-derived components and / or cell adhesion components. Treatment with blood-derived components and / or cell-adhesive components includes, for example, contacting serum and / or cell-adhesive components with the culture substrate and, if necessary, incubating for a predetermined period of time.
  • the serum and / or cell adhesion component used for coating may be the same type of serum as the seeded cell origin (homogeneous serum) or a different type of serum (heterologous serum), for example FBS, but is preferable. It is an allogeneic serum, more preferably a serum (autologous serum) obtained from an individual from which the seeded cells are derived. Other blood-derived components include albumin and platelet lysates. Examples of the cell adhesive component used for coating include extracellular matrix such as collagen, fibronectin, laminin, vitronectin, proteoglycan, glycosaminoglycan, cadoherin family, selectin family, and integrin family.
  • the seeding of cells on the culture medium can be performed by any known method and conditions. Seeding of cells into a culture medium may be carried out, for example, by injecting a cell suspension in which cells are suspended in a culture medium into a culture medium (culture container). For injection of the cell suspension, an instrument suitable for the injection operation of the cell suspension, such as a dropper or a pipette, can be used.
  • the seeding density of cells is set to a density capable of forming a sheet-like cell culture, and the density may vary depending on the desired cells, but those skilled in the art select an appropriate density from methods known in the art. can do.
  • Examples of higher densities include, for example, a density that reaches confluence, that is, a density at which cells are expected to cover the entire adhesive surface of the culture vessel when seeded, for example, cells come into contact with each other when seeded. It can be as dense as expected, the density at which contact inhibition occurs, or the density at which cell proliferation is substantially stopped by contact inhibition or higher.
  • the upper limit of the seeding density is not particularly limited, but if the seeding density is excessively high, more cells will die, resulting in inefficiency.
  • the seeding densities are about 5.0 ⁇ 10 5 pcs / cm 2 to about 1.0 ⁇ 10 7 pcs / cm 2 , about 5.0 ⁇ 10 5 pcs / cm 2 to about 5.
  • it is about 7.5 ⁇ 10 5 pieces / cm 2 to 3.0 ⁇ 10 6 pieces / cm 2 , and in another preferred aspect, it is about 1.76 ⁇ 10 6 pieces / cm 2 to. Approximately 2.33 ⁇ 10 6 pieces / cm 2 .
  • the seeded cell population may contain other cells (fibroblasts) as long as they contain the desired cells, and if the desired cells are skeletal myoblasts or muscle satellite cells, for example fibers. Further may include blast cells, vascular endothelial cells and the like.
  • the cell population the cell population collected from the tissue may be used as it is, or may be used after cryopreservation, pre-culture, removal of fibroblasts, or the like.
  • the seeded cell population is separated from a living tissue, seeded on a culture substrate (preferably on a flat culture substrate), adherently cultured, and then recovered. Is. Cryopreservation and thawing may be performed before or after such adhesive culture.
  • the culture conditions and the like may be the same as those for normal adhesive culture.
  • a commercially available culture container for adhesive culture may be used for culturing under 37 ° C. and 5% CO 2 conditions.
  • the seeding density of the cells may be any density as long as it does not interfere with the adhesion between the cells and / or the formation of the adhesion between the cells and the culture substrate, and may be, for example, a subconfluent density. It may be at or above a density that reaches confluence.
  • the culturing time may be such that adhesion between cells and / or adhesion between cells and the culture substrate is formed, and specifically, for example, 2 to 24 hours, 2 to 12 hours, and 2 to 6 hours. It may be about 2 to 4 hours.
  • the culture medium used in the production method of the present invention is not particularly limited as long as it can maintain the survival of cells, but typically, those containing amino acids, vitamins, and electrolytes as main components can be used.
  • the culture medium is based on a basal medium for cell culture.
  • basal medium is not limited to, for example, DMEM, MEM, F12, DMEM / F12, DME, RPMI1640, MCDB (MCDB102, 104, 107, 120, 131, 153, 199, etc.), L15, SkBM, RITC80. -7 and so on are included.
  • the basal medium may be used as it has a standard composition (for example, as it is on the market), or the composition may be appropriately changed depending on the cell type and cell conditions. Therefore, the basal medium used in the present invention is not limited to those having a known composition, and includes those in which one or more components are added, removed, increased or decreased. Transplantation media may also include additives such as normal serum (eg, bovine serum such as bovine fetal serum, horse serum, human serum, etc.) and various growth factors (eg, FGF, EGF, VEGF, HGF, etc.). However, when the sheet-shaped cell culture is produced under xenofree conditions, it is particularly preferable that it does not contain heterologous sera such as bovine serum and horse serum.
  • normal serum eg, bovine serum such as bovine fetal serum, horse serum, human serum, etc.
  • growth factors eg, FGF, EGF, VEGF, HGF, etc.
  • heterologous sera such as bovine serum and horse serum.
  • the present disclosure is characterized in that a graft-forming culture is performed using a graft-forming medium containing a cell adhesion component, whereby a high-quality graft can be formed even if the graft-forming medium is serum-free. It is effective. Therefore, in a preferred embodiment, the graft-forming medium is serum-free.
  • the implant is produced, comprising some or all of the above-mentioned implants, particularly those used in the production of sheet-like cell cultures, particularly sheet-like cell cultures that have not undergone growth culture.
  • the kit for is not limited to, for example, a container for separating biological tissue, a physiologically acceptable liquid for use in disruption, a homogenizer for separating skeletal myoblasts, and cells forming a transplant. (For example, cryopreserved cells, cells recovered by the recovery method of the present invention, etc.), culture medium, culture dish, instruments (for example, pipette, dropper, tweezers, etc.), instructions on a method for producing a sheet-shaped cell culture (for example).
  • a medium containing an instruction manual, a manufacturing method, and a medium for recording information on a method for recovering cryopreserved cells of the present invention such as a flexible disc, a CD, a DVD, a Blu-ray disc, a memory card, a USB memory, etc. Good.
  • the present invention relates to a method for treating a disease in the subject.
  • the diseases to be treated are as described above.
  • the term “treatment” shall include all types of medically acceptable prophylactic and / or therapeutic interventions aimed at the cure, temporary remission or prevention of disease, etc.
  • the term “treatment” is medically acceptable for a variety of purposes, including delaying or stopping the progression of a disease associated with a tissue abnormality, regressing or eliminating a lesion, preventing the onset or recurrence of the disease, and the like. Including interventions to be performed.
  • an ingredient that enhances the viability, engraftment and / or function of the implant, other active ingredients useful for treating the target disease, etc. are used in combination with the implant of the present disclosure. be able to.
  • the treatment method of the present disclosure may further include the step of producing the implant of the present disclosure according to the production method of the present disclosure.
  • the treatment method of the present disclosure further includes the step of collecting biological tissue from which a source of skeletal myoblasts and / or myosatellite cells for producing a graft from a subject is collected before the step of producing the graft. It may be included.
  • the subject from which the tissue from which the cells or skeletal myoblasts and / or muscle satellite cells are sourced is collected is the same individual as the subject to whom the cell culture, composition, implant, etc. is administered. ..
  • the subject from which the skeletal myoblasts and / or myoblasts or the tissue from which the skeletal myoblasts and / or muscle satellite cells are sourced is collected is a cell culture, composition, implant, or the like.
  • the subject to be administered is a separate body of the same species.
  • the subject from which the skeletal myoblast and / or myoblast or the tissue from which the skeletal myoblast and / or the muscle satellite cell is supplied is collected is different from the subject to which the implant or the like is administered. It is an individual.
  • the effective amount is, for example, an amount capable of suppressing the onset or recurrence of a disease, reducing symptoms, or delaying or stopping the progression (for example, size, weight, number of sheet-like cell cultures, etc.).
  • the amount is preferably an amount that prevents the onset and recurrence of the disease or cures the disease.
  • an amount that does not cause an adverse effect exceeding the benefit of administration is preferable.
  • Such an amount can be appropriately determined by, for example, a test in an experimental animal such as a mouse, a rat, a dog or a pig, or a disease model animal, and such a test method is well known to those skilled in the art.
  • the size of the tissue lesion to be treated can be an important index for determining the effective amount.
  • Examples of the administration method include intravenous administration, intramuscular administration, intraosseous administration, intrathecal administration, and direct application to tissues.
  • the frequency of administration is typically once per treatment, but multiple doses can be administered if the desired effect is not obtained.
  • the cell culture, composition, sheet-like cell culture or the like of the present invention may be fixed to the target tissue by a locking means such as a suture or a staple.
  • each configuration can be replaced with any configuration capable of exerting the same function, or any configuration can be added.
  • ⁇ Preliminary cleaning step> Approximately 3 g of tissue was collected from skeletal muscle collected from the lower limbs of pigs, and in tissue transport solution (HBSS (Hanks' Balanced Salt Solution, Life Technologies)), glucose injection (Termo) 1.6 mg / mL, gentamicin (Fuji Pharmaceutical Co., Ltd.) (Industrial Co., Ltd.) 0.1 mg / mL, Fungizone (Life Technologies) 2.5 ⁇ g / mL) was immersed and washed.
  • tissue transport solution HBSS (Hanks' Balanced Salt Solution, Life Technologies)
  • Comparative Example 1 Step of manually manipulating an instrument to chop [Comparative Example 1] ⁇ Steps to shred> Approximately 2 g of skeletal muscle was collected from the lower limbs of edible pigs, and tissue transport solution (Hanks' Balanced Salt Solution: GIBCO, Glucose 1.45 mg / mL: Otsuka Pharmaceutical Co., Ltd., Gentamycin 0.1 mg / mL: Fuji Pharmaceutical Co., Ltd.) , Fungizone 2.5 ⁇ g / mL: GIBCO) and washed. The washed skeletal muscle was then shredded in 10 mL of enzyme digestive juice (collagenase-containing solution) at room temperature. White tissue (connective tissue) was removed from this.
  • tissue transport solution Hort' Balanced Salt Solution: GIBCO, Glucose 1.45 mg / mL: Otsuka Pharmaceutical Co., Ltd., Gentamycin 0.1 mg / mL: Fuji Pharmaceutical Co., Ltd.
  • Comparative Example 2 Step of crushing by gentleMACS [Comparative Example 2] ⁇ Steps to crush with gentleMACS> After cutting the skeletal muscle tissue into 5 mm squares with a scalpel, it is put into gentleMACS C Tubes (Miltenyi Biotec KK, Order no: 130-093-237) together with 10 mL of enzyme digestive juice, and this is put into gentleMACS Octo Dissociator (Miltenyi Biotec KK,). It was submitted to Order no: 130-093-237) and the skeletal muscle tissue was crushed.
  • the crushing conditions in the gentleMACS Octo Dissociator were the following conditions 1 and 2.
  • ⁇ Culture step> The cells recovered from the enzyme treatment step were transferred to a culture flask (bottom area 175 cm 2 ) and cultured at 37 ° C. under 5% (V / V) CO 2 conditions. After culturing, cells were collected and the number of cells was counted.
  • Table 1 shows the results of Comparative Example 1 and Comparative Example 2.
  • shredded is skeletal muscle tissue shredded by hand according to the procedure of Comparative Example 1
  • gentleMACS1 is crushed under condition 1 according to the procedure of Comparative Example 2.
  • GenetleMACS2 means the ones crushed under the condition 2.
  • Comparative Example 3 Steps of manually manipulating the instrument to chop it [Comparative Example 3] Approximately 3 g of skeletal muscle tissue was collected from the lower limbs of two pig individuals (sample numbers: 633 and 805) and chopped by the same means as in Comparative Example 1 above after the pre-washing step.
  • Example 1 Step of crushing by pressing [Example 1] ⁇ Step to crush> Approximately 3 g of skeletal muscle tissue was collected from the lower limbs of the same two pig individuals as in Comparative Example 3 described above (sample numbers: 633 and 805), washed in the same procedure as the pre-washing step, and cut into 5 mm squares with a scalpel. After that, put 15 mL of the enzyme digestive solution (used in the shredding step) into a homogenize bag (Elmex, PYXON-20, code No. PX0020), and put this into a pressing homogenizer (Pro media SH-IIM). It was subjected to MEX, Code No. SH-2M)) and crushed for 15 minutes according to the equipment settings.
  • a homogenize bag Elmex, PYXON-20, code No. PX0020
  • FIG. 4 shows a homogenized bag containing the crushing treatment liquid immediately after the crushing treatment.
  • the skeletal muscle treated products obtained in Comparative Example 3 and Example 1 were treated according to the same procedure as the enzyme treatment steps of Comparative Example 1 and Comparative Example 2 described above.
  • the resulting cells were subjected to a culture step.
  • ⁇ Culture step> The cells recovered from the enzyme treatment step were transferred to a culture flask (bottom area 175 cm 2 ) and cultured at 37 ° C. under 5% (V / V) CO 2 conditions. After culturing, cells were collected and the number of cells was counted. Subculture was performed as needed.
  • the sample with sample number: 633 crushed by pressing was able to increase the number of cells as compared with the sample shredded through subculture.
  • the sample with sample number: 805 was able to increase the number of cells as compared with the shredded sample in both the primary culture and the subculture. Since more skeletal myoblasts than shredded tissue are cultured through subculture in this way, it is suggested that the crushing treatment by pressing can separate not only skeletal myoblasts but also many myosatellite cells. There is. Furthermore, it was clarified that the crushing treatment by pressing is suitable for the separation of stem cells because a significantly higher number of cells can be obtained than the general cell crushing treatment (gentleMACS).
  • Example 2 Step of crushing by pressing [Example 2] Four samples of about 3 g of skeletal muscle tissue were collected from the lower limbs of individual pigs and crushed for 5, 10, 15 and 20 minutes in the same procedure as in Example 1 above after the pre-washing step.
  • Example 3 Crushing step using a crushing container [Example 3] A separation container was prepared by heat-sealing so that a figure-eight protrusion was formed in the lower space of the homogenized bag (Elmex, PYXON-20, code No. PX0020). Two samples of about 3 g of skeletal muscle tissue were collected from the lower limbs of the same pig individual as in Comparative Example 4 described above, and after the pre-washing step as shown in FIG. 5, the skeletal muscle tissue was cut into 5 mm squares with a scalpel, and 15 mL of enzyme digestive juice (fine).
  • the skeletal muscle treated products obtained in Comparative Examples 4 and 2 were treated according to the same procedure as the enzyme treatment steps of Comparative Examples 1 and 2 described above.
  • the resulting cells were subjected to a culture step.
  • ⁇ Culture step> The cells recovered from the enzyme treatment step were transferred to a culture flask (bottom area 175 cm 2 ) and cultured at 37 ° C. under 5% (V / V) CO 2 conditions. After culturing, cells were collected and the number of cells was counted.
  • the number of recovered cells was the highest after 5 minutes of crushing, and the number of recovered viable cells decreased as the crushing time was lengthened.
  • Sufficient amounts of skeletal myoblasts and / or myosatellite cells are isolated by disrupting deep into the tissue, although viability is reduced when a crushing vessel is used.
  • the optimum separation method is a press crushing treatment for 5 minutes using a crushing container.
  • Example 4 Crushing step using a crushing container and a cushioning material [Example 4] Similar to Comparative Example 4 described above, about 4.01 g of skeletal muscle tissue was collected from the lower limbs of the pig, cut into 5 mm squares with a scalpel after the pre-cleaning step, and the same container as the separation container prepared in Example 3. Was prepared, 10 mL of the enzyme digestive solution was poured into the lower space, and the top of the figure-eight protruding portion was sealed with a heat seal. Prepare another homogenize bag (Elmex, PYXON-20, code No.
  • the skeletal muscle treated products obtained in Comparative Examples 5 and 4 were treated according to the same procedure and the same procedure as the enzyme treatment steps of Comparative Examples 1 and 2 described above.
  • the resulting cells were subjected to a culture step.
  • ⁇ Culture step> The cells recovered from the enzyme treatment step were transferred to a culture flask (bottom area 175 cm 2 ) and cultured at 37 ° C. under 5% (V / V) CO 2 conditions. After culturing, cells were collected and the number of cells was counted.
  • ⁇ Cell purity measurement step> The cultured cells were collected and a part of them was used for the purity measurement of skeletal myoblasts. Anti-CD56 antibody was reacted with each cell, and the proportion of CD56-positive cells (skeletal myoblast purity) was measured using a flow cytometer.
  • Comparative Example 5 The results of Comparative Example 5 and Example 4 are shown in Table 5.
  • "shredded” is a step of manually shredding according to the procedure of Comparative Example 4
  • Example 4 is a step of crushing by pressing using a sample crushing container and a cushioning material according to the procedure of Example 4. And then the ones that have been subjected to the step of being chopped by human hands.
  • Example 5 A combination of a step of chopping and a step of crushing [Example 5] About 3 g of skeletal muscle tissue was collected from the lower limbs of the same pig individual as in Comparative Example 6, and crushed for 2 minutes by the same procedure as in Example 4 using a crushing container. After opening this, it was transferred to a petri dish and shredded.
  • Comparative Examples 6 and 5 were treated according to the same procedure as the enzyme treatment steps of Comparative Examples 1 and 2 described above.
  • the resulting cells were subjected to a culture step.
  • ⁇ Culture step> The cells recovered from the enzyme treatment step were transferred to a culture flask (bottom area 175 cm 2 ) and cultured at 37 ° C. under 5% (V / V) CO 2 conditions. After culturing, cells were collected and the number of cells was counted.
  • Figure 6 shows the changes before crushing and after crushing for 2 minutes.
  • the results of Comparative Example 6 (A) and Example 5 (B) are shown in FIG. It was revealed that the combination of the step of shredding and the step of crushing by pressing (B) can significantly increase the number of skeletal myoblasts to be separated as compared with the step of shredding (A).
  • Example 6 Examination of sheet-shaped cell culture using the isolated cells obtained in Example 5 [Example 6] Sheet-shaped cell cultures were prepared using the cultured skeletal myoblasts separated in Example 5. 3.7 ⁇ 10 skeletal myoblasts suspended in DMEM / F12 medium (Thermo Fisher Scientific Inc.) containing 20% human serum in a temperature-responsive culture dish (UpCell (R) 12-well multi-well, CellSeed). The seeds were sown at 6 cells / well, and the cells were sheet-cultured at 37 ° C. and 5% CO 2 for 2 to 12 hours. After sheeting and culturing, the medium was removed, and 700 ⁇ L of cooled HBSS (+) (Thermo Fisher Scientific Inc.) was added and removed. This was repeated, and after the second addition of the buffer solution, the cells were allowed to stand for 10 minutes, and then gently pipetting was performed to completely exfoliate the sheet-shaped cell culture. The sheet cell culture is shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Mechanical Engineering (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2020/037090 2019-09-30 2020-09-30 生細胞分離用容器 Ceased WO2021065986A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021551354A JP7546584B2 (ja) 2019-09-30 2020-09-30 生細胞分離用容器
CN202080062738.4A CN114364784B (zh) 2019-09-30 2020-09-30 试样的粉碎方法
EP20873204.0A EP4026888A4 (en) 2019-09-30 2020-09-30 Container for separating live cells
US17/682,418 US20220275316A1 (en) 2019-09-30 2022-02-28 Container for separating live cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-179002 2019-09-30
JP2019179002 2019-09-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/682,418 Continuation US20220275316A1 (en) 2019-09-30 2022-02-28 Container for separating live cells

Publications (1)

Publication Number Publication Date
WO2021065986A1 true WO2021065986A1 (ja) 2021-04-08

Family

ID=75336948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/037090 Ceased WO2021065986A1 (ja) 2019-09-30 2020-09-30 生細胞分離用容器

Country Status (5)

Country Link
US (1) US20220275316A1 (https=)
EP (1) EP4026888A4 (https=)
JP (1) JP7546584B2 (https=)
CN (1) CN114364784B (https=)
WO (1) WO2021065986A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200022533A1 (it) * 2022-11-03 2024-05-03 Mirco Cavicchioli Dispositivo attivatore di un materiale agglomerato e rispettivi kit e procedimento di selezione

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02211865A (ja) 1989-02-10 1990-08-23 Kao Corp 細胞培養支持体材料
JPH0453678U (https=) * 1990-09-13 1992-05-07
JPH07284679A (ja) 1994-04-15 1995-10-31 Erumetsukusu:Kk ホモジナイザー
JP2002136570A (ja) * 2000-08-24 2002-05-14 Otsuka Pharmaceut Factory Inc 医療用複室容器
JP2003033177A (ja) 2001-07-24 2003-02-04 Mitsuo Okano 高密度細胞アレイ用基板、製造法、及びその利用方法
JP2007528755A (ja) 2003-08-01 2007-10-18 株式会社カルディオ 三次元組織構造体
JP2008062970A (ja) * 2006-09-07 2008-03-21 Oshio Sangyo Kk 包装袋
JP2010239891A (ja) * 2009-04-03 2010-10-28 Olympus Corp 脂肪組織分離装置
JP2011110368A (ja) 2009-11-30 2011-06-09 Terumo Corp シート状細胞培養物の製造方法
WO2019065135A1 (ja) * 2017-09-26 2019-04-04 富士フイルム株式会社 バッグ把持用クリップ、容器及び撹拌方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035737A1 (ja) * 2003-10-10 2005-04-21 Asahi Kasei Medical Co., Ltd. 細胞濃縮物の調製方法および細胞組成物
WO2005056748A1 (en) * 2003-12-08 2005-06-23 Covaris, Inc. Apparatus and methods for sample preparation
US8343129B2 (en) * 2006-06-15 2013-01-01 Metpro Ab Container, system and method for providing a solution
US8460267B2 (en) * 2008-11-28 2013-06-11 Terumo Kabushiki Kaisha Blood bag system and cassette
EP2386284A1 (en) * 2010-05-10 2011-11-16 B. Braun Melsungen AG Shape
CN108504539B (zh) * 2010-08-06 2021-11-02 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的系统和设备
FR3053051B1 (fr) * 2016-06-24 2022-11-11 Cellprothera Cassette et automate de culture cellulaire

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02211865A (ja) 1989-02-10 1990-08-23 Kao Corp 細胞培養支持体材料
JPH0453678U (https=) * 1990-09-13 1992-05-07
JPH07284679A (ja) 1994-04-15 1995-10-31 Erumetsukusu:Kk ホモジナイザー
JP2002136570A (ja) * 2000-08-24 2002-05-14 Otsuka Pharmaceut Factory Inc 医療用複室容器
JP2003033177A (ja) 2001-07-24 2003-02-04 Mitsuo Okano 高密度細胞アレイ用基板、製造法、及びその利用方法
JP2007528755A (ja) 2003-08-01 2007-10-18 株式会社カルディオ 三次元組織構造体
JP2008062970A (ja) * 2006-09-07 2008-03-21 Oshio Sangyo Kk 包装袋
JP2010239891A (ja) * 2009-04-03 2010-10-28 Olympus Corp 脂肪組織分離装置
JP2011110368A (ja) 2009-11-30 2011-06-09 Terumo Corp シート状細胞培養物の製造方法
WO2019065135A1 (ja) * 2017-09-26 2019-04-04 富士フイルム株式会社 バッグ把持用クリップ、容器及び撹拌方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4026888A4

Also Published As

Publication number Publication date
JPWO2021065986A1 (https=) 2021-04-08
JP7546584B2 (ja) 2024-09-06
EP4026888A1 (en) 2022-07-13
CN114364784B (zh) 2024-02-02
US20220275316A1 (en) 2022-09-01
CN114364784A (zh) 2022-04-15
EP4026888A4 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
JP7282232B2 (ja) 接着状態の細胞培養物の改変方法
JP2016509863A5 (https=)
KR20160048029A (ko) 제대혈 수집 및 세포의 분리를 위한 세포, 방법 및 장치
Yang et al. Effect of aged bone marrow microenvironment on mesenchymal stem cell migration
JP7546584B2 (ja) 生細胞分離用容器
US11760976B2 (en) Stem cells and decellularization of tissue matrix from cord tissue
JP7256818B2 (ja) 心筋細胞のシート化方法
JP2021052658A (ja) 生体由来組織からの生細胞の分離方法
KR20250174023A (ko) 지방 유래 중간엽 줄기세포를 조혈 줄기/전구세포로 전환하고 혈액세포로 분화시키기 위한 시스템 및 방법과 그 응용
JP7575392B2 (ja) 心筋細胞のシート化方法
JP7550778B2 (ja) Ｃｄ５６陽性細胞の比率を高めるための方法
RU2620981C2 (ru) Способ получения культуры мезенхимных стволовых клеток человека из периваскулярного пространства вены пупочного канатика
JPWO2020067443A1 (ja) 体細胞のシート化方法
US20240026299A1 (en) Stem cell and tissue cultures and their products
Alves et al. Mesenchymal stem cell therapy for equine tendinitis
US20220265901A1 (en) Method for enhancing activity in a graft
JP2021132541A (ja) 生体由来組織を細切するための方法
US20200390936A1 (en) Method for cryopreserving cells
WO2016206703A2 (en) Biomimetic amniotic membrane niche for stem cells
JP2021132597A (ja) Ｃｄ５６陽性細胞を含む細胞培養物を製造するための方法
JP2021052662A (ja) 移植片の活性を高める方法
JP2021132584A (ja) シート状細胞培養物の剥離に関する評価方法
Fröhlich et al. CTESS Symposium 2015
WO2021065970A1 (ja) 体細胞を含有するシート状物の作製方法
WO2020067434A1 (ja) 細胞の凍結保存方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20873204

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021551354

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020873204

Country of ref document: EP

Effective date: 20220407

WWW Wipo information: withdrawn in national office

Ref document number: 2020873204

Country of ref document: EP